Reckitt Benckiser Shares Plunge After Infant-Formula Verdict
By Michael Susin
Reckitt Benckiser shares fell sharply after a jury in an Illinois court sided with a plaintiff in a case relating to infant-formula Enfamil made by its Mead Johnson unit.
At 1553 GMT, shares in the U.K. consumer-goods company were down 17% to GBP43.52, putting the stock on track for its worst one-day percentage fall ever and taking it back to 2013 levels.
Reckitt--which houses Dettol, Harpic and Durex among its brands--said Friday that it strongly disagrees with the jury's decision to fault Mead Johnson and that it doesn't believe that any of its products cause necrotizing enterocolitis, a life-threatening gastrointestinal disease.
The company's statement came after it was reported an Illinois jury ordered its infant-formula unit, Mead Johnson, to pay $60 million in compensation related to the death of a premature baby who was fed Enfamil.
"We will pursue all options to overturn the verdict," it said, adding that the allegations from the plaintiff were not supported by the science.
Mead Johnson Nutrition Company was acquired by Reckitt in June 2017.
"Based on the size of this fine, the share move is massively overstating the initial impact, which suggests investors are preparing for more to come," Hargreaves Lansdown head of money and markets, Susannah Streeter, said in market comment.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
March 15, 2024 12:21 ET (16:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth